Jacobs Levy Equity Management Inc. Purchases New Position in Bio-Rad Laboratories, Inc. $BIO

Jacobs Levy Equity Management Inc. purchased a new stake in Bio-Rad Laboratories, Inc. (NYSE:BIO) in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 3,349 shares of the medical research company’s stock, valued at approximately $816,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Quarry LP acquired a new position in Bio-Rad Laboratories in the first quarter valued at approximately $29,000. Curat Global LLC acquired a new position in Bio-Rad Laboratories in the first quarter valued at approximately $34,000. Allworth Financial LP boosted its holdings in Bio-Rad Laboratories by 260.0% in the first quarter. Allworth Financial LP now owns 144 shares of the medical research company’s stock valued at $36,000 after purchasing an additional 104 shares in the last quarter. Headlands Technologies LLC boosted its holdings in Bio-Rad Laboratories by 64.1% in the first quarter. Headlands Technologies LLC now owns 356 shares of the medical research company’s stock valued at $87,000 after purchasing an additional 139 shares in the last quarter. Finally, Twin Tree Management LP acquired a new position in Bio-Rad Laboratories in the first quarter valued at approximately $87,000. 65.24% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on BIO. Wall Street Zen cut Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research note on Friday, August 22nd. Wells Fargo & Company boosted their price objective on Bio-Rad Laboratories from $245.00 to $265.00 and gave the company an “equal weight” rating in a research note on Friday, August 1st. Royal Bank Of Canada boosted their price objective on Bio-Rad Laboratories from $387.00 to $409.00 and gave the company an “outperform” rating in a research note on Friday, August 1st. Finally, Zacks Research upgraded Bio-Rad Laboratories from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 26th. Three research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $333.50.

Bio-Rad Laboratories Price Performance

Bio-Rad Laboratories stock opened at $280.32 on Friday. Bio-Rad Laboratories, Inc. has a 12 month low of $211.43 and a 12 month high of $387.99. The company has a debt-to-equity ratio of 0.17, a current ratio of 5.12 and a quick ratio of 3.67. The business has a 50 day simple moving average of $272.32 and a 200-day simple moving average of $252.08. The stock has a market capitalization of $7.59 billion, a PE ratio of 23.90 and a beta of 0.95.

Bio-Rad Laboratories (NYSE:BIO) last announced its quarterly earnings data on Thursday, July 31st. The medical research company reported $2.61 earnings per share for the quarter, beating analysts’ consensus estimates of $1.93 by $0.68. Bio-Rad Laboratories had a return on equity of 4.01% and a net margin of 12.50%.The company had revenue of $651.60 million for the quarter, compared to analyst estimates of $614.82 million. During the same quarter in the previous year, the company earned $3.11 EPS. The firm’s revenue for the quarter was up 2.1% compared to the same quarter last year. Bio-Rad Laboratories has set its FY 2025 guidance at EPS. Equities analysts predict that Bio-Rad Laboratories, Inc. will post 10.81 earnings per share for the current year.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.